HM 16390
Alternative Names: HM-16390; LAPS IL-2 analog - Hanmi PharmaceuticalLatest Information Update: 05 Sep 2024
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 04 Sep 2024 Phase-I clinical trials in Solid tumours (SC) prior to September 2024 (Hanmi Pharmaceutical pipeline, September 2024)
- 29 Jun 2024 US FDA approves IND application for HM 16390 in Solid Tumours
- 03 Jun 2024 Hanmi Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in USA